（注）この論文はopen access代金を支払い、open accessになったことの通知のようです。内容を訂正したわけではありません。
https://www.liebertpub.com/doi/10.1089/mab.2023.0033.correx
Kaneko MK, Suzuki H, Kato Y.
Establishment of a novel cancer-specific anti-HER2 monoclonal antibody H2Mab-250/H2CasMab-2 for breast cancers
Monoclon. Antib. Immunodiagn. Immunother.,43(2), 35-43, DOI: 10.1089/mab.2023.0033, 2024 (PDF;online;preprint)
Correction to: Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H2Mab-250/H2CasMab-2 for Breast Cancers’’ by Kaneko et al. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 2024;43(2):35–43; doi: 10.1089/mab.2023.0033
In the April 2024 issue of Monoclonal Antibodies in Immunodiagnosis and Immunotherapy (vol. 43, no. 2; pp. 35–43) the article entitled “Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H2Mab-250/H2CasMab-2 for Breast Cancers” by Kaneko et al. requires correction.
This article was originally published under the copyright of Mary Ann Liebert, Inc. publishers. It has now been updated to reflect Open Access, with copyright transferring to the author(s), and a Creative Commons License (CC-BY) added (http://creativecommons.org/licenses/by/4.0). The CC-BY license went into effect April 16, 2024.
The online version of this article has been corrected to reflect this.